The company – which specializes in solutions for injectable drug administration – officially opened the new facility last week, welcoming more than 35 employees who will work at the site.
The investment is in addition to West’s $400m in global expansion efforts, and will support the company’s capability enhancements in chemistry, material sciences, and biology, while meeting the growing needs of its products and services to support complex sensitive molecules and the changing regulatory environment.
“As the scientific industry gets increasingly more sophisticated with new technology, improving our understanding of our patients will come more sharply into focus," said Anya Harry, M.D., Ph.D., Vice President of R&D and Chief Medical Officer/Applied Research.
"West’s new research and development lab allows us to bring our one hundred years of scientific and technical expertise together so we can continue to define what is possible in improving patients’ health.
“The lab is an essential part of West’s overall growth to better support our customers, our growing partnerships, and find new ways to conduct our research.”
The new R&D lab at Radnor is a direct response to West's focus on delivery of advanced therapy and new therapeutic experiences across containment and systems, says the company.
“West is committed to growing its business through strategic R&D investments to drive innovation,” said Scott Young Ph.D., VP Venture & External Collaboration, Research & Development at West. “The R&D lab at Radnor will enhance our collaborations with existing and future customers to innovate and accelerate their drug delivery strategies.”
Headquartered in Exton, Pennsylvania, West generated $2.89bn in net sales in 2022.